Tong Lu

1.3k total citations
31 papers, 861 citations indexed

About

Tong Lu is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Tong Lu has authored 31 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Tong Lu's work include Lymphoma Diagnosis and Treatment (10 papers), HER2/EGFR in Cancer Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Tong Lu is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), HER2/EGFR in Cancer Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Tong Lu collaborates with scholars based in China, United States and France. Tong Lu's co-authors include Changxiao Liu, F. Xu, Chuan Li, Yühong Huang, Yan Sun, Boli Zhang, Feifei Du, Junling Yang, Xiumei Gao and Wei Niu and has published in prestigious journals such as Advanced Drug Delivery Reviews, Frontiers in Immunology and Pharmaceutical Research.

In The Last Decade

Tong Lu

31 papers receiving 828 citations

Peers

Countries citing papers authored by Tong Lu

Since Specialization

Citations

This map shows the geographic impact of Tong Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tong Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tong Lu more than expected).

Fields of papers citing papers by Tong Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tong Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tong Lu. The network helps show where Tong Lu may publish in the future.

Co-authorship network of co-authors of Tong Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Tong Lu. A scholar is included among the top collaborators of Tong Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tong Lu. Tong Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings 2024 ·Advanced Drug Delivery Reviews ·Michael Z. Liao, Dan Lu, Tong Lu, Leonid Gibiansky, Rong Deng, Divya Samineni, Randall Dere, (unknown), Jamie Hirata, Ben‐Quan Shen, Donglu Zhang, Dongwei Li, Chunze Li, Dale Miles	2
2	Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration 2023 ·The Journal of Clinical Pharmacology ·Matts Kågedal, (unknown), (unknown), (unknown), Mauricio Maia, Tong Lu, (unknown), Angelica Quartino, Jeffrey R. Willis, Jin Y. Jin, Katie F. Maass	4
3	gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Tong Lu, (unknown), (unknown), (unknown), (unknown), (unknown), Jin Y. Jin, Matts Kågedal	2
4	Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma 2023 ·Frontiers in Immunology ·Randall Dere, Richard L. Beardsley, Dan Lü, Tong Lu, Grace Ku, Gabriel Man, Văn Hùng Nguyễn, Surinder Kaur	4
5	Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis 2022 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Tong Lu, Siv Jönsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina Tang, Young S. Oh, René Bruno, (unknown)	5
6	Motif C in nonstructural protein 5 of duck Tembusu virus is essential for viral proliferation 2021 ·Veterinary Microbiology ·Tong Lu, (unknown), Wei Zhang, Bowen Jiang, Miao Zeng, Mingshu Wang, Renyong Jia, Dekang Zhu, Mafeng Liu, Xinxin Zhao, Qiao Yang, Ying Wu, Shun Chen, Anchun Cheng	1
7	Decreased virulence of duck Tembusu virus harboring a mutant NS2A with impaired interaction with STING and IFNβ induction 2021 ·Veterinary Microbiology ·Wei Zhang, Bowen Jiang, Miao Zeng, Tong Lu, Tao Hu, Jiaqi Guo, Mingshu Wang, Renyong Jia, Dekang Zhu, Mafeng Liu, Xinxin Zhao, Qiao Yang, Ying Wu, Shaqiu Zhang, Yunya Liu, Ling Zhang, Yanling Yu, Leichang Pan, Anchun Cheng, Shun Chen	1
8	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma 2020 ·Cancer Chemotherapy and Pharmacology ·Colby S. Shemesh, Priya Agarwal, Tong Lu, Calvin Lee, Randall Dere, Xiaobin Li, Chunze Li, Jin Y. Jin, Sandhya Girish, Dale Miles, Dan Lü	11
9	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma 2020 ·Pharmaceutical Research ·Dan Lü, Tong Lu, (unknown), Leonid Gibiansky, Priya Agarwal, Colby S. Shemesh, Randall Dere, Uzor C. Ogbu, Jamie Hirata, Pascal Chanu, Sandhya Girish, Jin Y. Jin, Chunze Li, Dale Miles	13
10	Discovery of Novel 2,4,6-Trisubstituted Pyrimidine Derivatives as Succinate Dehydrogenase Inhibitors 2020 ·Chinese Journal of Organic Chemistry ·(unknown), (unknown), Tingting Xiao, Guilan Zhang, Tingting Zhang, Tong Lu, Xiaorong Tang	11
11	Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma 2020 ·Cancer Chemotherapy and Pharmacology ·(unknown), Tong Lu, Grace Ku, Hao Ding, Tomohisa Saito, Leonid Gibiansky, Priya Agarwal, Xiaobin Li, Jin Y. Jin, Sandhya Girish, Dale Miles, Chunze Li, Dan Lü	6
12	Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study 2019 ·Clinical Pharmacokinetics ·Rong Deng, Leonid Gibiansky, Tong Lu, Priya Agarwal, Hao Ding, Xiaobin Li, Smita Kshirsagar, Dan Lü, Chunze Li, Sandhya Girish, Jue Wang, Michelle Boyer, Kathryn Humphrey, Kevin J. Freise, Ahmed Hamed Salem, John F. Seymour, Arnon P. Kater, Dale Miles	12
13	Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study 2019 ·Leukemia & lymphoma ·Rong Deng, Leonid Gibiansky, Tong Lu, Xiaobin Li, Dan Lü, Chunze Li, Sandhya Girish, Jue Wang, Michelle Boyer, (unknown), Kathryn Humphrey, Kevin J. Freise, Ahmed Hamed Salem, John F. Seymour, Arnon P. Kater, Dale Miles	9
14	Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug–Drug Interaction Prediction 2015 ·Clinical Pharmacokinetics ·Yuan Chen, Fang Ma, Tong Lu, Nageshwar Budha, Jin Y. Jin, Jane R. Kenny, Harvey Wong, Cornelis E. C. A. Hop, (unknown)	23
15	Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach 2013 ·Investigative Ophthalmology & Visual Science ·Lu Xu, Tong Lu, Lisa Tuomi, Nelson L. ‘Shasha’ Jumbe, Jianfeng Lü, Steve Eppler, Peter Kuebler, Lisa A. Damico‐Beyer, Amita Joshi	161
16	Absorption and Disposition of Ginsenosides after Oral Administration of Panax notoginseng Extract to Rats 2009 ·Drug Metabolism and Disposition ·Houfu Liu, Junling Yang, Feifei Du, Xiumei Gao, (unknown), Yühong Huang, F. Xu, Wei Niu, Fengqing Wang, Yu Mao, Yan Sun, Tong Lu, Changxiao Liu, Boli Zhang, Chuan Li	319
17	Plasma and Urinary Tanshinol from Salvia miltiorrhiza (Danshen) Can Be Used as Pharmacokinetic Markers for Cardiotonic Pills, a Cardiovascular Herbal Medicine 2008 ·Drug Metabolism and Disposition ·Tong Lu, Junling Yang, Xiumei Gao, Ping Chen, Feifei Du, Yan Sun, Feng‐Qing Wang, F. Xu, Hongcai Shang, Yühong Huang, Yi Wang, (unknown), Changxiao Liu, Boli Zhang, Chuan Li	112
18	Determination of limonin in rat plasma by liquid chromatography–electrospray mass spectrometry 2005 ·Journal of Pharmaceutical and Biomedical Analysis ·Yan Liang, Lin Xie, Xiaodong Liu, Tong Lu, Guangji Wang, Yuzhu Hu	16
19	Gender differences in limonin pharmacokinetics in rats 2005 ·European Journal of Drug Metabolism and Pharmacokinetics ·Yan Liang, Li Xie, (unknown), (unknown), Tong Lu, G. J. Wang	6
20	Gender difference in ranolazine pharmacokinetics in rats 2003 ·European Journal of Drug Metabolism and Pharmacokinetics ·Xian-De Liu, Lin Xie, Yan Liang, (unknown), Tong Lu	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact